Comprehensive Stock Comparison
Compare Protagonist Therapeutics, Inc. (PTGX) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | REGN | 1.0% revenue growth vs PTGX's -100.0% |
| Value | REGN | Lower P/E (17.3x vs 25.4x) |
| Stability / Safety | PTGX | Lower D/E ratio (1.7% vs 8.7%) |
| Dividends | REGN | 0.4% yield; 1-year raise streak; PTGX pays no meaningful dividend |
| Momentum (1Y) | PTGX | +145.0% vs REGN's +12.4% |
| Efficiency (ROA) | REGN | 11.1% ROA vs PTGX's -19.5%, ROIC 12.4% vs -21.8% |
Who Each Stock Is For
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing peptide-based drugs for blood disorders and inflammatory diseases. It generates revenue primarily through collaboration agreements — notably with Janssen Biotech — and has no commercial products yet, relying on milestone payments and potential future royalties. The company's key advantage is its proprietary peptide discovery platform that enables the development of orally available peptide therapeutics, a challenging area in drug development.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
REGN leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). PTGX leads in 2 (Total Returns, Risk & Volatility).
Financial Metrics (TTM)
REGN and PTGX operate at a comparable scale, with $14.3B and $0 in trailing revenue. On growth, REGN holds the edge at +2.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PTGXProtagonist Thera… | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $14.3B |
| EBITDAEarnings before interest/tax | -$158M | $4.2B |
| Net IncomeAfter-tax profit | -$130M | $4.5B |
| Free Cash FlowCash after capex | $58M | $3.2B |
| Gross MarginGross profit ÷ Revenue | — | +86.3% |
| Operating MarginEBIT ÷ Revenue | — | +25.7% |
| Net MarginNet income ÷ Revenue | — | +31.4% |
| FCF MarginFCF ÷ Revenue | — | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -122.6% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -134.8% | -2.5% |
Valuation Metrics
| Metric | PTGXProtagonist Thera… | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $5.8B | $107.6B |
| Enterprise ValueMkt cap + debt − cash | $5.6B | $91.4B |
| Trailing P/EPrice ÷ TTM EPS | -44.92x | 18.84x |
| Forward P/EPrice ÷ next-FY EPS est. | 25.45x | 17.25x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.98x |
| EV / EBITDAEnterprise value multiple | — | 21.64x |
| Price / SalesMarket cap ÷ Revenue | — | 7.50x |
| Price / BookPrice ÷ Book value/share | 9.52x | 2.72x |
| Price / FCFMarket cap ÷ FCF | 99.91x | 26.36x |
Profitability & Efficiency
REGN delivers a 14.4% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-21 for PTGX. PTGX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to REGN's 0.09x. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs PTGX's 4/9, reflecting strong financial health.
| Metric | PTGXProtagonist Thera… | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | -21.2% | +14.4% |
| ROA (TTM)Return on assets | -19.5% | +11.1% |
| ROICReturn on invested capital | -21.8% | +12.4% |
| ROCEReturn on capital employed | -24.0% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.02x | 0.09x |
| Net DebtTotal debt minus cash | -$118M | -$16.2B |
| Cash & Equiv.Liquid assets | $128M | $18.9B |
| Total DebtShort + long-term debt | $10M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | — | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in PTGX five years ago would be worth $34,422 today (with dividends reinvested), compared to $16,977 for REGN. Over the past 12 months, PTGX leads with a +145.0% total return vs REGN's +12.4%. The 3-year compound annual growth rate (CAGR) favors PTGX at 78.4% vs REGN's 1.1% — a key indicator of consistent wealth creation.
| Metric | PTGXProtagonist Thera… | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +5.6% | +0.8% |
| 1-Year ReturnPast 12 months | +145.0% | +12.4% |
| 3-Year ReturnCumulative with dividends | +467.7% | +3.4% |
| 5-Year ReturnCumulative with dividends | +244.2% | +69.8% |
| 10-Year ReturnCumulative with dividends | +687.0% | +104.7% |
| CAGR (3Y)Annualised 3-year return | +78.4% | +1.1% |
Risk & Volatility
PTGX is the less volatile stock with a -0.11 beta — it tends to amplify market swings less than REGN's 0.58 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | PTGXProtagonist Thera… | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.11x | 0.58x |
| 52-Week HighHighest price in past year | $96.54 | $821.11 |
| 52-Week LowLowest price in past year | $35.97 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +95.4% | +95.2% |
| RSI (14)Momentum oscillator 0–100 | 62.7 | 49.1 |
| Avg Volume (50D)Average daily shares traded | 594K | 687K |
Analyst Outlook
Wall Street rates PTGX as "Buy" and REGN as "Buy". Consensus price targets imply 21.4% upside for PTGX (target: $112) vs 9.7% for REGN (target: $857). REGN is the only dividend payer here at 0.44% yield — a key consideration for income-focused portfolios.
| Metric | PTGXProtagonist Thera… | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $111.75 | $857.17 |
| # AnalystsCovering analysts | 24 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | 100 | 1,048.61 | +948.6% |
| Regeneron Pharmaceu… (REGN) | 100 | 162.46 | +62.5% |
Protagonist Therape… (PTGX) returned +244% over 5 years vs Regeneron Pharmaceu… (REGN)'s +70%. A $10,000 investment in PTGX 5 years ago would be worth $34,422 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | $0.00 | $0.00 | — |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
Protagonist Therapeutics, Inc.'s revenue grew from $0M (2016) to $0M (2025) — a 0.0% CAGR. Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | -184.2% | 63.3% | +134.4% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | -5.72 | -2.05 | +64.2% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
Protagonist Therapeutics, Inc.'s EPS grew from $-5.72 (2016) to $-2.05 (2025). Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
Protagonist Therapeutics, Inc. generated $58M FCF in 2025 (+153% vs 2021). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
PTGX vs REGN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is PTGX or REGN a better buy right now?
Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 18.8x trailing P/E (17.3x forward), making it the more compelling value choice. Analysts rate Protagonist Therapeutics, Inc. (PTGX) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PTGX or REGN?
On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 17.3x.
03Which is the better long-term investment — PTGX or REGN?
Over the past 5 years, Protagonist Therapeutics, Inc. (PTGX) delivered a total return of +244.2%, compared to +69.8% for Regeneron Pharmaceuticals, Inc. (REGN). A $10,000 investment in PTGX five years ago would be worth approximately $34K today (assuming dividends reinvested). Over 10 years, the gap is even starker: PTGX returned +687.0% versus REGN's +104.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PTGX or REGN?
By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc. (PTGX) is the lower-risk stock at -0.11β versus Regeneron Pharmaceuticals, Inc.'s 0.58β — meaning REGN is approximately -628% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — PTGX or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus 0.0% for Protagonist Therapeutics, Inc. — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus 0.0% for PTGX. At the gross margin level — before operating expenses — REGN leads at 86.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is PTGX or REGN more undervalued right now?
On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 17.3x forward P/E versus 25.4x for Protagonist Therapeutics, Inc. — 8.2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PTGX: 21.4% to $111.75.
07Which pays a better dividend — PTGX or REGN?
In this comparison, REGN (0.4% yield) pays a dividend. PTGX does not pay a meaningful dividend and should not be held primarily for income.
08Is PTGX or REGN better for a retirement portfolio?
For long-horizon retirement investors, Protagonist Therapeutics, Inc. (PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.11), +687.0% 10Y return). Both have compounded well over 10 years (PTGX: +687.0%, REGN: +104.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between PTGX and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.